Abstract
BackgroundRecent studies reported an association between the 2‐2 phenotype of haptoglobin (Hp 2‐2) and increased cardiorenal morbidity in nonsurgical diabetic patients. Our goal was to determine whether the Hp 2‐2 phenotype was associated with acute kidney injury (AKI) after elective cardiac surgery in patients with diabetes mellitus.Methods and ResultsWe prospectively enrolled 99 diabetic patients requiring elective cardiac surgery with cardiopulmonary bypass. Haptoglobin phenotypes were determined by gel electrophoresis. Cell‐free hemoglobin, haptoglobin, and total serum bilirubin were quantified as hemolysis markers. The primary outcome was postoperative AKI, as defined by the Acute Kidney Injury Network classification. The incidence of AKI was significantly higher in Hp 2‐2 patients compared with patients without this phenotype (non–Hp–2‐2; 55.6% versus 27%, P<0.01). The need for renal replacement therapy was also significantly higher in the Hp 2‐2 group (5 patients versus 1 patient, P=0.02). Thirty‐day mortality (3 versus 0 patients, P=0.04) and 1‐year mortality (5 versus 0 patients, P<0.01) were also significantly higher in patients with the Hp 2‐2 phenotype. In multivariable analysis, Hp 2‐2 was an independent predictor of postoperative AKI (P=0.01; odds ratio: 4.17; 95% confidence interval, 1.35–12.48).ConclusionsHp 2‐2 phenotype is an independent predictor of postoperative AKI and is associated with decreased short and long‐term survival after cardiac surgery in patients with diabetes mellitus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.